Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Weak transient response of chronic uveitic macular edema to intravitreal bevacizumab (Avastin).

Literature DB >> 17219112

Weak transient response of chronic uveitic macular edema to intravitreal bevacizumab (Avastin).

Focke Ziemssen, Christoph M Deuter, Nicole Stuebiger, Manfred Zierhut.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 2007 PMID： 17219112 DOI： 10.1007/s00417-006-0512-2

Source DB: PubMed Journal: Graefes Arch Clin Exp Ophthalmol ISSN： 0721-832X Impact factor: 3.535

× No keyword cloud information.

10 in total

Review 1. Medical treatment of cystoid macular edema.

Authors: Aniki Rothova
Journal: Ocul Immunol Inflamm Date: 2002-12 Impact factor: 3.070

Review 2. Intravitreal triamcinolone acetonide for treatment of intraocular oedematous and neovascular diseases.

Authors: Jost B Jonas
Journal: Acta Ophthalmol Scand Date: 2005-12

3. Retinal pigment epithelial tear following intravitreal bevacizumab injection for neovascular age-related macular degeneration.

Authors: Faik Gelisken; Focke Ziemssen; Michael Voelker; Karl U Bartz-Schmidt
Journal: Acta Ophthalmol Scand Date: 2006-12

4. Impact of macular edema on visual acuity in uveitis.

Authors: Charlotte W T A Lardenoye; Bram van Kooij; Aniki Rothova
Journal: Ophthalmology Date: 2006-08 Impact factor: 12.079

5. Intravitreal bevacizumab (Avastin) for refractory pseudophakic cystoid macular edema.

Authors: John O Mason; Michael A Albert; Rachel Vail
Journal: Retina Date: 2006-03 Impact factor: 4.256

6. Interferon alfa-2a: a new treatment option for long lasting refractory cystoid macular edema in uveitis? A pilot study.

Authors: Christoph M E Deuter; Ina Koetter; Ilhan Guenaydin; Nicole Stuebiger; Manfred Zierhut
Journal: Retina Date: 2006-09 Impact factor: 4.256

7. Proinflammatory functions of vascular endothelial growth factor in alloimmunity.

Authors: Marlies E J Reinders; Masayuki Sho; Atsushi Izawa; Ping Wang; Debabrata Mukhopadhyay; Kerith E Koss; Christopher S Geehan; Andrew D Luster; Mohamed H Sayegh; David M Briscoe
Journal: J Clin Invest Date: 2003-12 Impact factor: 14.808

8. Intravitreal bevacizumab therapy for neovascular age-related macular degeneration: a pilot study.

Authors: Maura Lucy Abrahám-Marin; Carlos Fernando Cortés-Luna; Griselda Alvarez-Rivera; Myriam Hernández-Rojas; Hugo Quiroz-Mercado; Virgilio Morales-Cantón
Journal: Graefes Arch Clin Exp Ophthalmol Date: 2006-09-28 Impact factor: 3.535

9. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration.

Authors: M Clauss; M Gerlach; H Gerlach; J Brett; F Wang; P C Familletti; Y C Pan; J V Olander; D T Connolly; D Stern
Journal: J Exp Med Date: 1990-12-01 Impact factor: 14.307

10. Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells.

Authors: K Hattori; S Dias; B Heissig; N R Hackett; D Lyden; M Tateno; D J Hicklin; Z Zhu; L Witte; R G Crystal; M A Moore; S Rafii
Journal: J Exp Med Date: 2001-05-07 Impact factor: 14.307

10 in total

14 in total

Weak transient response of chronic uveitic macular edema to intravitreal bevacizumab (Avastin).

Review 1. Medical treatment of cystoid macular edema.

Review 2. Intravitreal triamcinolone acetonide for treatment of intraocular oedematous and neovascular diseases.

3. Retinal pigment epithelial tear following intravitreal bevacizumab injection for neovascular age-related macular degeneration.

4. Impact of macular edema on visual acuity in uveitis.

5. Intravitreal bevacizumab (Avastin) for refractory pseudophakic cystoid macular edema.

6. Interferon alfa-2a: a new treatment option for long lasting refractory cystoid macular edema in uveitis? A pilot study.

7. Proinflammatory functions of vascular endothelial growth factor in alloimmunity.

8. Intravitreal bevacizumab therapy for neovascular age-related macular degeneration: a pilot study.

9. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration.

10. Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells.

1. Visual loss from hyphema following intravitreal bevacizumab.

2. Recurrence of acute anterior inflammation after intravitreal injection of bevacizumab in uveitis.

3. Bevacizumab in inflammatory eye disease.

4. [Therapy of intermediate uveitis].

5. Intravitreal bevacizumab: an analysis of the evidence.

6. Ranibizumab in choroidal neovascularisation associated with ocular sarcoidosis.

Review 7. Intravitreal Anti-VEGF Injections in Pregnancy: Case Series and Review of Literature.

Review 8. Intravitreal anti-vascular endothelial growth factor medications during pregnancy: current perspective.

Review 9. [Treatment of pseudophakic cystoid macular edema].

10. Interventions for the treatment of uveitic macular edema: a systematic review and meta-analysis.